Island Pharmaceuticals Secures U.S. Patent for Galidesivir in Treating Marburg and Filoviridae Viruses
Island Pharmaceuticals Limited (ASX: ILA) has been granted U.S. Patent Number 12,508,266 by the U.S. Patent and Trademark Office for the use of its Galidesivir antiviral drug in treating filoviridae viruses, including Marburg and Ebola. This patent provides protection through to 14 October 2031 for a broad range of claims related to Galidesivir’s use in treating filoviridae infections, which are classified as biological select agents due to their potential to pose severe threats to public health and safety. This approval strengthens Island’s expanding intellectual property (IP) portfolio, following the company’s earlier patent grants for Galidesivir’s application to treat Covid-19. The successful patent grant underscores Island's ongoing commitment to advancing the clinical development of Galidesivir, particularly its application for Marburg virus treatment under the FDA's Animal Rule. The company will continue progressing its development alongside expanding its IP protection.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
Island Pharmaceuticals Secures U.S. Patent for Galidesivir in Treating Marburg and Filoviridae Viruses
Island Pharmaceuticals Limited (ASX: ILA) has been granted U.S. Patent Number 12,508,266 by the U.S. Patent and Trademark Office for the use of its Galidesivir antiviral drug in treating filoviridae viruses, including Marburg and Ebola. This patent provides protection through to 14 October 2031 for a broad range of claims related to Galidesivir’s use in treating filoviridae infections, which are classified as biological select agents due to their potential to pose severe threats to public health and safety. This approval strengthens Island’s expanding intellectual property (IP) portfolio, following the company’s earlier patent grants for Galidesivir’s application to treat Covid-19. The successful patent grant underscores Island's ongoing commitment to advancing the clinical development of Galidesivir, particularly its application for Marburg virus treatment under the FDA's Animal Rule. The company will continue progressing its development alongside expanding its IP protection.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au